Securities code: 301111 securities abbreviation: Guangdong Jiangxi Wannianqing Cement Co.Ltd(000789) Announcement No.: 2022008 summary of 2021 annual report of Guangdong Jiangxi Wannianqing Cement Co.Ltd(000789) Pharmaceutical Co., Ltd
1、 Important note: the summary of this annual report comes from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development plan, investors should carefully read the full text of the annual report in the media designated by the CSRC. All directors personally attended the meeting of the board of directors to consider this annual report. The audit opinion of Huaxing Certified Public Accountants (special general partnership) on the company’s financial report this year is: standard unqualified opinion. Changes of accounting firm during the reporting period: the accounting firm of the company has not changed this year and is still Huaxing accounting firm (special general partnership). Tips on non-standard audit opinions □ applicable √ not applicable the company was not profitable at the time of listing and is not profitable at present □ applicable √ not applicable to the profit distribution plan of common stock or the plan of converting accumulation fund into share capital in the reporting period considered by the board of directors √ applicable □ not applicable
The company’s profit distribution plan for ordinary shares reviewed and approved by the board of directors is: take 1 Shanghai Pudong Development Bank Co.Ltd(600000) 00 shares as the base, distribute cash dividends of 1.60 yuan (including tax) to all shareholders for every 10 shares, give bonus shares of 0 shares (including tax), and transfer capital reserve to all shareholders for every 10 shares.
Preferred stock profit distribution plan for the reporting period adopted by the board of directors □ applicable √ not applicable II. Basic information of the company 1. Company profile
Stock abbreviation: Yue Jiangxi Wannianqing Cement Co.Ltd(000789) Stock Code: 301111
Shenzhen Stock Exchange
Stock abbreviation before change (if any) none
Contact person and contact information secretary of the board of directors securities affairs representative
Name: Chen Xiuyan, Zheng zepeng
Office address: No. 08, area 16, Chaoyang Road, Jinyuan Industrial City, Shantou
Fax: 075488119688
Tel: 075488119688075488119688
E-mail [email protected]. [email protected].
2. Introduction to main business or products during the reporting period
The industry of the company is pharmaceutical manufacturing, and the company’s main business is the R & D, production and sales of Chinese patent medicine. During the reporting period, the company achieved an operating income of 349788900 yuan,
An increase of 2.59% over the same period last year; The net profit attributable to the shareholders of the listed company was 577819 million yuan, a decrease of 8.54% over the same period last year, and the non profit attributable to the shareholders of the listed company was deducted
The net profit from recurring profit and loss was 549946 million yuan, a decrease of 2.99% over the same period last year. The decrease in net profit was mainly caused by the decline in the gross profit of mask products. This year due to the mask Market
The demand stabilized and the price returned to the normal level. The sales revenue of the company’s mask products was 133718 million yuan, a year-on-year decrease of 77.63%, and the gross profit was 405200 yuan, a year-on-year decrease
98.48%。
(1) Introduction to main products of the company
The application scope of the company’s products covers biliary tract, hypoglycemic, heat clearing and detoxification, gynecology, tonic, pediatrics, cough relieving and asthma, cardio cerebrovascular, cold
13 fields of medicine, such as rheumatology and urology. The company has 101 drug approval numbers, of which 32 are original products and 10 are new products
Exclusive varieties, 4 products are exclusive dosage forms, 16 products are listed in the national basic drug catalogue and 39 products are listed in the national medical insurance catalogue. In 2020, due to covid-19 pneumonia,
The company has increased the production and sales of masks. The products mainly include disposable medical masks, medical surgical masks, kn95 masks, etc. the applicable population includes adults
And children.
The main products and functions of the company are as follows:
Indications main product name main product picture function main indications remarks
Clearing away heat, dampness and gallbladder. It is used for prescription drugs for damp heat of liver and gallbladder, hypochondriac pain and bitter mouth caused by national medical insurance catalogue class A and national anti-inflammatory Lidan tablets; Acute cholecystitis, bile duct basic drug catalogue, national low price drug catalogue and national inflammation with the above symptoms. Initiative
Biliary tract
Clearing heat and dampness, benefiting gallbladder and expelling stones. It is used for prescription drugs for damp heat of liver and gallbladder, hypochondriac pain and bile distention caused by national medical insurance catalogue class B and national Danshitong capsule. Symptoms include right hypochondriac distention and pain, high-quality products of the administration of traditional Chinese medicine, grade II ruffian vomiting of traditional Chinese medicine, yellow urine and bitter mouth; Cholelithiasis, gallbladder protection varieties (2 Yunnan Yuntou Ecology And Environment Technology Co.Ltd(002200) 9) and exclusive inflammation see the above symptoms. species
Supplementing qi and nourishing Yin, nourishing spleen and kidney.
Diabetes, prescription drugs, national health insurance directory, and national hypoglycemic Shenqi hypoglycemic tablet are used for type II diabetes. Catalogue of basic drugs, catalogue of national low-cost drugs and exclusive dosage forms
Heat clearing, detoxification and anti-inflammatory. It is a prescription drug for colds and upper breathing. It is a secondary protected variety of traditional Chinese medicine. It is a kind of Kumu injection for clearing heat and detoxification, which is the first in China, including respiratory tract infection, acute tonsillitis, enteritis and fine (20062012)
Bacillary dysentery, etc.
Heat clearing and detoxification, dryness and dampness stopping, insecticidal and antipruritic. Prescription drugs, class B of the national medical insurance catalogue and Fuyanping capsule of the national gynecology category are used for injection in damp heat, loss of appointment with pulse, red leucorrhea, low-cost drug catalogue, Yin itching and Yin swelling of the secondary protected variety of traditional Chinese medicine, trichomonas, mold and bacteria (2 Yunnan Yuntou Ecology And Environment Technology Co.Ltd(002200) 9), exclusive dosage forms Vaginitis, vulvitis, etc. Initiative
Replenish qi and spleen, nourish blood and calm nerves. Used for heart and spleen deficiency
Guipiye shortness of breath, palpitation, insomnia and dreaminess, dizziness, double leg cross medicine, Beijing Medical Insurance
Fatigue and loss of appetite.
Tonic class
Gujing Bushen pill can warm the spleen and kidney. It is used for deficiency and cold of spleen and kidney, reducing mental fatigue by eating,
Over the counter drugs, exclusive varieties
The waist is sour and the body is tired.
Nourishing the liver and kidney, nourishing the heart and calming the mind. For liver and kidney deficiency,
Naolibao pill causes forgetfulness, insomnia, irritability and more dreams,
Non prescription drugs, the first in China
Hot flashes, night sweats, mental fatigue and physical fatigue; Neurasthenia see above
State the syndrome.
Clearing away heat and toxin, dispelling phlegm and relieving cough, eliminating stagnation and moderate. It is the first time to use double span medicine, class B of national medical insurance catalogue and national pediatric Jianer Qingjie solution in oral erosion, cough, sore throat and loss of appetite
Abdominal distension, fullness, etc.
Regulating qi and resolving phlegm, relieving cough and asthma, tonifying qi and warming kidney. use
Zhubei Dingchuan pill for relieving cough and asthma is an exclusive and national initiative in the treatment of bronchial asthma, chronic bronchitis and other prescription drugs
Chronic illness, asthma and cough, excessive phlegm and saliva, etc.
Medical device masks are used for disposable health care in ordinary environment-
(2) Industry pattern and development trend
In December 2020, the State Food and drug administration put forward in the implementation opinions on promoting the inheritance, innovation and development of traditional Chinese medicine that it is of great significance in promoting the implementation, adjusting the registration classification and opening up of traditional Chinese medicine
On the basis of innovative measures such as the registration and application path with the characteristics of traditional Chinese medicine and the construction of the “Three Combinations” evaluation evidence system, we will further encourage the development of clinical value oriented Chinese medicine
Drug innovation and development. This provides favorable conditions for drug R & D and listing, and ushers in new opportunities for the innovative development of traditional Chinese medicine industry.
At the end of 2021, the centralized procurement of 19 provinces and cities of Chinese patent medicine alliance led by Hubei Province was completed, which was the first centralized procurement of Chinese patent medicine alliance in China. In this centralized volume procurement, 182 products of 157 enterprises participated in the quotation, and the procurement scale was nearly 10 billion yuan; Finally, 97 enterprises and 111 products were selected, with a selection rate of 62% and an average decline in prices
42.27%, with a maximum decrease of 82.63%. On February 11, 2022, the relevant person in charge of the national medical insurance administration said in public that the next step is to promote the speed-up and expansion of centralized purchase and centralized drug purchase
The comprehensive development of chemical medicine, Chinese patent medicine and biological medicine will further expand the centralized mining scope of Chinese patent medicine. With the deepening of reform policies such as volume procurement,
China’s traditional Chinese medicine industry will have a trend of high-quality development, and the industry concentration will be further improved.
In January 2022, the one of the leading group one of the “one belt, one road” construction project jointly issued by the State Administration of traditional Chinese medicine and the “leading the whole area” was launched to promote the integration of high-quality Chinese medicine.
